Moderna Inc (NAS:MRNA)
$ 132.68 3.62 (2.8%) Market Cap: 50.85 Bil Enterprise Value: 42.17 Bil PE Ratio: 0 PB Ratio: 3.86 GF Score: 67/100

Moderna Inc To Discuss SARS-CoV-2 Vaccine (mRNA-1273) Interim Phase 1 Data Transcript

May 18, 2020 / 12:30PM GMT
Release Date Price: $80 (+19.96%)
Operator

Good morning, and welcome to the Moderna's Conference Call. (Operator Instructions) Please be advised that the call is being recorded. At this time, I'd like to turn the call over to Lavina Talukdar, Head of Investor Relations at Moderna.

Lavina Talukdar
Moderna, Inc. - Head of IR

Thank you, operator. Good morning, everyone, and welcome to Moderna's Conference Call to discuss the interim Phase I data for mRNA-1273, our vaccine against the novel coronavirus. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the Investors section of our website.

Speaking on today's call are Stéphane Bancel, our Chief Executive Officer; Tal Zaks, our Chief Medical Officer; Stephen Hoge, our President; and Lorence Kim, our Chief Financial Officer.

Before we begin, please note that this conference call will include forward-looking statements. Please see Slide 2 of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot